Introduction
further the development of a serology-driven differential flavivirus diagnosis, 93 particularly between ZIKV and DENV, allowing for accurate diagnosis that will 94 improve patient management. The application can also be further expanded to study 95 sero-prevalence and vaccine strategies. 96
Ethics statement 98
Written informed consent was obtained from participants in accordance with the 99 tenets of the Declaration of Helsinki. Study protocols of Singapore ZIKV (2016 -2018 100 and DENV (2010) (2011) (2012) 
Study subjects and sample collection 109

Singapore ZIKV patients 110
Collection of specimens from subjects during the ZIKV outbreak in 2016 was 111 previously described [24] . Briefly, 65 patients that were RT-PCR positive for ZIKV in 112 whole blood or urine, and negative for DENV RT-PCR were enrolled [25] . Whole 113 blood specimens were collected in EDTA-coated vacutainer tubes (Becton 114 Dickinson) after peripheral venipuncture and were centrifuged at 12000 rpm for 10 115 min. Plasma was collected and heat-inactivated for 30 min at 56°C before storage at 116 -80°C. Specimens were obtained over a period of six time points: (1) acute [2-7 days 117 post-illness onset (pio)], (2) early convalescent (10-14 days pio), (3) late 118 convalescent (1 month pio), (4) early recovery (3 months pio), (5) late recovery (5-6 119 months pio), and (6) full recovery (1 year pio) phases. 120 121 Twenty DENV patient serum samples (2010) (2011) (2012) collected before the ZIKV 123 outbreak were used in this study [26] . Patients were DENV PCR and/or NS1 positive 124 upon hospital admission, and were a combination of the following: one unknown 125 serotype, six DENV-1, seven DENV-2, three DENV-3, and three DENV-4 patients. 126
Serum samples used were obtained at late convalescent phase (21-37 days pio). 127 128
Thailand patients 129
Archived serum samples from an undifferentiated fever study conducted at Shoklo 130 Malaria Research Unit (SMRU) were used. Five DENV patients were confirmed by 131 gold standard paired serology, and all but one was DENV PCR positive. Five 132 bacteria-infected patients were diagnosed with leptospirosis, scrub typhus, murine 133 typhus or Streptococcus pneumoniae infections, or a combination of above, and all 134
were DENV PCR and DENV NS1, IgM and IgG RDT negative. Eight patients with 135 unknown diagnoses were negative for the above pathogens by serology, blood 136 culture and PCR. Convalescent serum samples used were collected at 14-20 days 137
pio. 138 139
Viruses 140
ZIKV Polynesian isolate (H/PF/2013) was obtained from the European Virus Archive 141 (EVA). DENV-3 was used as a reference DENV serotype because it is widespread in 142
Southeast Asia [27] [28] [29] [30] , and was kindly provided by the National Public Health 143 Laboratory (NPHL), Singapore. CHIKV SGP011 was isolated from a patient [31] . 144
Viruses were propagated in VeroE6 cells (ATCC) and purified via ultracentrifugation 145
[32] before being titered by standard plaque assays in VeroE6 cells [33, 34] . 146
Virion-based ELISA 148
Antibody titers were determined by a virion-based ELISA as previously described 149 [18, 32, [34] [35] [36] . Briefly, purified virus was immobilized on 96-well maxisorp microtiter 150 plates overnight (Nunc). Wells were blocked with 0.05% PBST [0.05% Tween-20 151 (Sigma-Aldrich) in PBS] containing 5% skim milk (Nacalai Tesque) at 37°C for 1.5 h. 152
Heat-inactivated patient and pooled healthy control plasma samples at 1:200 to 153 1:8000 dilutions prepared in PBST with 2.5% milk were incubated at 37°C for 1 h. 154 HRP-conjugated goat anti-human IgM or IgG (H+L) (Invitrogen) or mouse anti-155 human IgG1, IgG2, IgG3 and IgG4 (Thermo Fischer Scientific) antibodies were used 156 for detection. Reactions were developed using TMB (3,3,5,5-tetramethyl benzidine) 157 substrate (Sigma-Aldrich) and terminated with Stop reagent (Sigma-Aldrich), and 158 absorbance was measured at 450 nm in a microplate autoreader (Tecan) [18,32,34-159 36] . ELISA readings were conducted in duplicates or triplicates. 160 161
Sero-neutralization 162
Neutralizing capacity of antibodies from ZIKV patients were determined via flow 163 cytometry [37] . Briefly, pooled patient and healthy plasma samples at 1:1000 dilution 164 were incubated with ZIKV or DENV-3 at MOI 10 for 2 h at 37°C with gentle agitation 165 (350 rpm). Virus-antibody suspensions were then added in duplicates to HEK 293T 166 cells (ATCC) at 37°C. After 2 h, media were removed and Dulbecco's Modified Eagle 167 Medium (DMEM; HyClone) with 10% fetal bovine serum (FBS; HyClone) were 168 added. After 48 h, cells were harvested and stained as described [37] , using ZIKV 169 NS3 protein-specific rabbit polyclonal antibody [38] 
Epitopes determination 178
Linear peptide libraries 179
The sequences used for the design of biotinylated linear peptides of prM, E and NS1 180 proteins were derived from ZIKV Polynesian isolate (KJ776791) and consensus 181 sequence of DENV-3 strains (KR296743, KF973487, EU081181, KF041254, 182 JF808120, JF808121, KJ189293, KC762692, KC425219, KJ830751, KF973479, and 183 AY099336) [32, 34, 36] . Peptides were generated as a ZIKV and DENV peptide-pair 184 of corresponding sequences. Preliminary epitope screening was used with a library 185 of peptides (Mimotopes) consisting of 18-mer overlapping sequences. Five peptides 186 were combined to form one pooled peptide set. Screening and validation of patients 187 were done with higher purity of peptides (≥90%, EMC microcollections GmbH) with 188 lengths ranging from 11 to 22-mer (Supplementary Table 1 Figures 1A-B ) 243
were used as the healthy control pool, and set as a baseline reference. 244
Anti-ZIKV IgM and IgG levels of ZIKV patients from the Singapore outbreak in 245 2016 [24, 25, 38] were longitudinally assessed using virion-based ELISA [18,32,34-246 36] . Majority of the patients showed a robust ZIKV-specific humoral response 247 ( Figures 1A-C, Supplementary Figure 1C ). Anti-ZIKV IgM was detected as early as 248 in the acute phase (2-7 days pio), and peaked at early convalescent (10-14 days 249 pio), before decreasing during the recovery phases (3 months to 1 year pio) (Figures 250 1A and 1C, Supplementary Figure 1C) . ZIKV-specific IgG titers peaked at early 251 convalescent, persisted at high levels during late recovery, and were still detectable 252 a year after infection ( Figures 1B-C, Supplementary Figure 1C ). These patients were 253 also screened for the presence of DENV-specific antibodies and 80% of the patients 254 were negative for anti-DENV IgM in samples taken at the acute phase 255
(Supplementary Figures 1D and 1F) . However, 75% of the patients were found to 256 have anti-DENV IgG (Supplementary Figures 1E-F) , suggesting that ZIKV IgG, but 257 not IgM, cross-reacts with DENV. 258 IgG isotypes produced by ZIKV patients were then determined and highest 259 titers of anti-ZIKV IgG1 and IgG3 subtypes were produced at early convalescent for 260 IgG3, and late convalescent for IgG1 ( Figure 1D ). To determine if antibodies 261 carried out via flow cytometry. Efficient neutralization (71% to 93%) was observed in 263 early and late convalescent stages ( Figure 1E ), whilst weak neutralization (37% to 264 47%) was seen in late and full recovery stages ( Figure 1F ). Neutralization capacity of 265 ZIKV patients correlated with levels of anti-ZIKV IgG (Supplementary Figures 1C and  266 4A). Plasma from these patients only minimally neutralized DENV (Supplementary 267 Figures 1G-H Figure 1C) . 276
Results specifically showed two common flavivirus (pools 1 and 21), six potential 277 ZIKV-specific (pools 6, 10, 11, 16, 17 and 24) and one potential DENV-specific (pool 278 19) pools were identified within the ZIKV and DENV proteome (Supplementary Table  279 2, Supplementary Figure 2) . Thereafter, new peptides selectively designed based on 280 exposed residues and computational predictions were re-synthesized for subsequent 281 Figure 2 ). These differences could be due to interferences of the 284 pooled peptides, while single peptides allowed for more enhanced specific binding. 285
Nevertheless, six potential common flavivirus peptides were identified which 286 displayed less than 0.05 relative difference in the binding capacity between ZIKV and 287 DENV patients (peptides 7, 36, 38, 39, 46, 49) (Table 1, In order to characterize the changes in epitope recognition by ZIKV patients over 296 time, the common flavivirus (green) and ZIKV-specific peptides (red) were screened 297 with plasma of ZIKV patients in acute, late convalescent, and full recovery phases. 298
For the common flavivirus hits, more than 60% of the ZIKV patients were able to 299 recognize the six peptide-pairs at late convalescent and beyond ( Figure 3A) . 300
However, at the acute phase, only peptides 7, 36 and 38 were recognized by ZIKV 301 patients ( Figure 3A ). In terms of binding capacity, there was equal binding between 302 ZIKV and DENV peptide-pairs over time for peptides 7, 36, 38 and 49 ( Figure 3B ). 303
For ZIKV-specific epitopes, more than 60% of the ZIKV patient samples were 304 able to recognize peptides 3 and 26 ( Figure 3A To assess the diagnostic performance of identified epitopes, the 13 peptides were 313 screened using patient serum samples from a Thailand cohort that had DENV, 314 bacteria, or unknown infections. Results of a randomized selection of Singapore 315 ZIKV and DENV patients were also analyzed in parallel (Supplementary Table 3) . 316
Interestingly, results showed a wide range of specificity and sensitivity for 317 each peptide (Table 2, Figure 4A ). ZIKV-specific peptide 26 (amino acid residues 318 271-288) on the E protein of domain I/II (EDI/II) had the best sensitivity and 319 specificity profile (80% and 85.7% respectively) (Table 2, Figure 4A ). Nevertheless, 320 eight peptides (common flavivirus peptides 36, 38, 46, 49; ZIKV-specific peptides 3, 321 26, 32; and DENV-specific peptide 9) showed more than 50% sensitivity and 322 specificity (Table 2, Figure 4A ), and were selected for further evaluation. These 323 peptides were used to "diagnose" the patients (Supplementary Table 4) , and the 324 performance of the peptide combination based on the epitope groupings were 325 determined collectively (Table 2, Figure 4B ). Although the common flavivirus (green) 326 and DENV-specific (blue) groups demonstrated modest measurements, the ZIKV-327 specific (red) peptide mix showed a robust specificity of 96.4% (Table 2, Figure 4B ). 328
Furthermore, when the anti-peptide IgG response of patients was plotted in a 329 principal component analysis (PCA), it was observed that patients of different 330 diagnoses and cohorts formed separate clusters, and ZIKV patients stood out when 331 compared to the healthy control ( Figure 4C ). To identify peptides with discriminating 332 power, the binding capacity of positive peptides were calculated. The virus-specific 333 ZIKV and DENV epitopes were significantly differential ( Figure 4D ). Peptide 32 334
(amino acid residues 453-470 on E protein) was the best performing ZIKV-specific 335 epitope, and was able to distinguish Singapore ZIKV patients from bacteria and 336 unknown infections from Thailand ( Figures 4D-E) . DENV-specific peptide 9 (amino 337 acid residues 78-92 on prM) could be used to differentiate Singapore DENV patients 338 from bacteria-infected patients from Thailand ( Figure 4E ). Overall, we have identified 339 the best differential epitopes to differentiate between DENV and ZIKV patients. 340 ZIKV patients were shown to produce high levels of ZIKV-specific IgG antibodies. 342
Specifically, IgG1 and IgG3 were the subclasses induced following ZIKV infection, 343 closely resembling DENV-infected patients [41] . Although patients from this cohort 344 had detectable DENV IgG levels due to the high level of cross-reactivity among 345 flaviviruses [7] [8] [9] [10] , DENV neutralization was significantly less efficient compared to 346 ZIKV, indicating that the antibodies were ZIKV-specific ( Figures 1E-F and 49 (amino acid residues 315-326) were identified as ZIKV-specific in other 360 patient cohorts from South America [45, 46] . However, it remains to be seen if these 361 peptides could be used to detect all flaviviruses such as yellow fever virus (YFV) and 362
Japanese encephalitis virus (JEV). 363
Differential ZIKV and DENV epitopes identified were located across prM, E 364 and NS1. Of interest, DENV-specific peptide 17 (amino acid residues 131-149) and 365 35% and 51% amino acid identity between ZIKV and DENV respectively [8] , 367 whereas ZIKV-specific peptide 32 is located on the stem ( Figure 3D ). It would also 368 be useful to assess the use of the identified peptides as a ZIKV vaccine target, 369 particularly peptides 26 and 32. Interestingly, despite the similarity between the 370 sequence of these ZIKV and DENV peptide-pairs (Supplementary Table 1), they 371 were able to distinguish ZIKV and DENV patients. Moreover, ZIKV patients at 372 different disease stages have different peptide recognition, and the current set-up 373 could identify ZIKV infection at any point, independent of the patients' level of ZIKV-374 specific antibodies (Supplementary Figure 4B-C) . However, given that the identified 375 epitopes were screened and validated using adult patient samples, it would be 376 important to assess how these epitope profiles will perform in other patient cohorts, 377 specifically ZIKV-infected pregnant women from Brazil [36] . 378 Intriguingly, the Singapore DENV and Thailand DENV patients were not 379 clustered together in the PCA ( Figure 4B ). Most of the Singapore DENV patients 380 selected for validation had moderate to severe forms of plasma leakage, a clinical 381 feature of severe manifestations of DENV infection [48] , whereas DENV patients 382 from Thailand displayed mild symptoms (unpublished data). The latter being 383 "negative" in our assays could thus be due to differences in epitope recognition in 384 different DENV disease states [40] , and the different strain of viruses circulating in 385 a ZIKV (n=10) and DENV (n=10) patients from Singapore, and DENV (n=5), bacteria (n=5) and unknown (n=8) patients from 585
Thailand were used in the diagnostic evaluation. 
